These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18092832)

  • 21. Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.
    Hajian B; Scocchera E; Keshipeddy S; G-Dayanandan N; Shoen C; Krucinska J; Reeve S; Cynamon M; Anderson AC; Wright DL
    PLoS One; 2016; 11(8):e0161740. PubMed ID: 27580226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
    Suling WJ; Reynolds RC; Barrow EW; Wilson LN; Piper JR; Barrow WW
    J Antimicrob Chemother; 1998 Dec; 42(6):811-5. PubMed ID: 10052907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
    Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
    Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of three crystal structure determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase.
    Cody V; Luft JR; Pangborn W; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2003 Sep; 59(Pt 9):1603-9. PubMed ID: 12925791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular modeling studies of Yersinia pestis dihydrofolate reductase.
    Oliveira AA; Rennó MN; de Matos CA; Bertuzzi MD; Ramalho TC; Fraga CA; França TC
    J Biomol Struct Dyn; 2011 Oct; 29(2):351-67. PubMed ID: 21875154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways.
    Hardy LW; Matthews W; Nare B; Beverley SM
    Exp Parasitol; 1997 Nov; 87(3):157-69. PubMed ID: 9371081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antifolate inhibitors for Mycobacterium avium.
    Barrow EW; Suling WJ; Seitz LE; Reynolds RC; Barrow WW
    Med Chem; 2006 Sep; 2(5):505-10. PubMed ID: 17017990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
    Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
    J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from
    Ribeiro JA; Hammer A; Libreros-Zúñiga GA; Chavez-Pacheco SM; Tyrakis P; de Oliveira GS; Kirkman T; El Bakali J; Rocco SA; Sforça ML; Parise-Filho R; Coyne AG; Blundell TL; Abell C; Dias MVB
    ACS Infect Dis; 2020 Aug; 6(8):2192-2201. PubMed ID: 32603583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
    Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
    Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: design, synthesis and antifolate activity.
    Zhang Z; Wu J; Ran F; Guo Y; Tian R; Zhou S; Wang X; Liu Z; Zhang L; Cui J; Liu J
    Eur J Med Chem; 2009 Feb; 44(2):764-71. PubMed ID: 18555562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
    Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
    Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
    Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
    ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.
    Debnath AK
    J Med Chem; 2002 Jan; 45(1):41-53. PubMed ID: 11754578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase.
    Johnson JM; Meiering EM; Wright JE; Pardo J; Rosowsky A; Wagner G
    Biochemistry; 1997 Apr; 36(15):4399-411. PubMed ID: 9109647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
    Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
    Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
    Gangjee A; Devraj R; Queener SF
    J Med Chem; 1997 Feb; 40(4):470-8. PubMed ID: 9046337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.